Conversion From Cyclosporine to Fk506 for Salvage of Immunocompromised Pediatric Liver Allografts Efficacy, Toxicity, and Dose Regimen in 23 Children

Rapamycin Inhibits Proliferation of Epstein-Barr Virus–Positive B-cell Lymphomas Through Modulation of Cell-Cycle Protein Expression

“…Moreover, the mortality rate in PTLD can reach 50% (13). Immunosuppressive drugs contribute to the development of PTLD by inhibiting cytotoxic T lymphocyte responses that normally control the expansion of EBV-infected lymphoblasts (14,15). In contrast, immunosuppressive drugs may have direct effects on EBV-transformed B cells that could influence PTLD-associated lymphoma growth.…”

A Randomized Trial of Ganciclovir versus Ganciclovir Plus Immune Globulin for Prophylaxis Against Epstein-Barr Virus Related Posttransplant Lymphoproliferative Disorder

“…PTLD occurs in approximately 2-5% of all organ transplant recipients and encompasses a diverse spectrum of manifestations. The incidence among children is significantly higher than in adults, with rates as high as 15-20% for some categories of pediatric transplant recipients (8,9). Children are particularly affected because they are most often EBV-seronegative pretransplant.…”

Primary calcification in post-transplantation lymphoproliferative disorder involving the hepatic graft: an exceptional finding

“…The disorder is defined as an abnormal proliferation of B lymphocytes involving various tissues and occurring in patients receiving immunosuppressive therapy, such as cyclosporin A, OKT 3 or FK 506 [2][3][4][5][6]. The role of EBV in the unrestricted proliferation of B cells is also strongly emphasized [7].…”